{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:22:58Z","timestamp":1787318578408,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>IGF-1 is an essential neurotrophin produced peripherally and in the brain. Impairments in the brain IGF-1 concentrations might be responsible for some aspects of major depressive disorder (MDD) pathogenesis, whereas peripheral IGF-1 could have the marker value. We aimed: 1) to compare serum IGF-1 levels in MDD patients and healthy controls (HC); 2) to elucidate possible associations between changes in IGF-1 expression and crucial characteristics of the current depressive episode, MDD course; 3) to evaluate IGF-1 dynamics after 8\u00a0weeks` vortioxetine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seventy-eight MDD patients (according to DSM-5) and 47 HC were enrolled. Serum IGF-1, psychopathological (MADRS, CGI) and neuropsychological parameters (PDQ-5, RAVLT, TMT-B, DSST) were analyzed in all subjects at admission and 48 patients after 8\u00a0weeks` vortioxetine treatment. AUC-ROCs were calculated to determine if the value of serum IGF-1 could separate MDD patients from HC. Multiple regression models were performed to explore relationships between IGF-1 and depressive episode\u2019s symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MDD patients had significantly higher serum IGF-1 levels than HC (228 (183\u2013312) ng\/ml vs 153 (129\u2013186) ng\/ml,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). IGF-1 had a good diagnostic value for predicting MDD in the whole sample with AUC of 0.820 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). For a cutoff of 178.00\u2009ng\/ml, the sensitivity and specificity were 83 and 71%, respectively, and the number needed to misdiagnose was 5, indicating that only 1 of 5 tests give an invalid result. Among MADRS items, only reported sadness, inner tension, and concentration difficulties were significantly positively associated with serum IGF-1 concentrations. Vortioxetine treatment significantly attenuated IGF-1 levels and improved all psychopathological, neuropsychological parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Significant associations between IGF-1 levels and hypothymia, anxiety, and cognitive disturbances may indicate a pathogenic role of IGF-1 for the mentioned symptoms. We assume that the activity of the cerebral-hepatic axis increases in response to insufficient IGF-1 brain expression in MDD patients, whereas, vortioxetine treatment restores cerebral IGF-1 concentrations and, consequently, decreases its compensatory production by the liver.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      registered at ClinicalTrials.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03187093\">NCT03187093<\/jats:ext-link>\n                      ). First posted on 14th June 2017.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-020-02636-7","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T03:02:45Z","timestamp":1588906965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study"],"prefix":"10.1186","volume":"20","author":[{"given":"Oleg A.","family":"Levada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6160-4604","authenticated-orcid":false,"given":"Alexandra S.","family":"Troyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina Y.","family":"Pinchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"issue":"7526","key":"2636_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/515180a","volume":"515","author":"K Smith","year":"2014","unstructured":"Smith K. Mental health: a world of depression. Nature. 2014;515(7526):181.","journal-title":"Nature."},{"issue":"23","key":"2636_CR2","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","volume":"289","author":"RC Kessler","year":"2003","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095\u2013105.","journal-title":"JAMA."},{"key":"2636_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.psychres.2017.01.060","volume":"250","author":"CL Vandeleur","year":"2017","unstructured":"Vandeleur CL, Fassassi S, Castelao E, Glaus J, Strippoli MF, Lasserre AM, et al. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry Res. 2017;250:50\u20138.","journal-title":"Psychiatry Res"},{"key":"2636_CR4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.","edition":"5"},{"key":"2636_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/da.22227","volume":"31","author":"RS Duman","year":"2014","unstructured":"Duman RS. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety. 2014;31:4.","journal-title":"Depress Anxiety"},{"key":"2636_CR6","first-page":"279","volume":"9","author":"Y Li","year":"2015","unstructured":"Li Y, Pehrson AL, Waller JA, Dale E, Sanchez C, Gulinello M. A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc\/Arg3.1)\u2018s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression. Front Neurosci. 2015;9:279.","journal-title":"Front Neurosci"},{"issue":"1","key":"2636_CR7","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.3390\/ph9010009","volume":"9","author":"F Darcet","year":"2016","unstructured":"Darcet F, Gardier AM, Gaillard R, David DJ, Guilloux JP. Cognitive dysfunction in major depressive disorder. A translational review in animal models of the disease. Pharmaceuticals (Basel). 2016;9(1):E9.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2636_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3389\/fncel.2015.00521","volume":"9","author":"D Rial","year":"2016","unstructured":"Rial D, Lemos C, Pinheiro H, Duarte JM, Gon\u00e7alves FQ, Real JI, et al. Depression as a glial-based synaptic dysfunction. Front Cell Neurosci. 2016;9:521.","journal-title":"Front Cell Neurosci"},{"issue":"Suppl 2","key":"2636_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/jnc.13580","volume":"139","author":"JD Sweatt","year":"2016","unstructured":"Sweatt JD. Neural plasticity and behavior\u2014sixty years of conceptual advances. J Neurochem. 2016;139(Suppl 2):179\u201399.","journal-title":"J Neurochem"},{"issue":"1","key":"2636_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1385\/NMM:5:1:011","volume":"5","author":"RS Duman","year":"2004","unstructured":"Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. NeuroMolecular Med. 2004;5(1):11\u201325.","journal-title":"NeuroMolecular Med"},{"issue":"1","key":"2636_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00592-010-0227-z","volume":"48","author":"M Annunziata","year":"2011","unstructured":"Annunziata M, Granata R, Ghigo E. The IGF system. Acta Diabetol. 2011;48(1):1\u20139.","journal-title":"Acta Diabetol"},{"issue":"7","key":"2636_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1210\/er.2004-0024","volume":"26","author":"VC Russo","year":"2005","unstructured":"Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev. 2005;26(7):916\u201343.","journal-title":"Endocr Rev"},{"issue":"6","key":"2636_CR13","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S1734-1140(13)71523-8","volume":"65","author":"E Szczesny","year":"2013","unstructured":"Szczesny E, Slusarczyk J, Glombik K, Budziszewska B, Kubera M, Lason W, et al. Possible contribution of IGF-1 to depressive disorder. Pharmacol Rep. 2013;65(6):1622\u201331.","journal-title":"Pharmacol Rep"},{"key":"2636_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12991-017-0161-3","volume":"16","author":"OA Levada","year":"2017","unstructured":"Levada OA, Troyan AS. Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder. Ann General Psychiatry. 2017;16:38.","journal-title":"Ann General Psychiatry"},{"key":"2636_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jad.2019.03.040","volume":"250","author":"OA Levada","year":"2019","unstructured":"Levada OA, Troyan AS. Cognitive-functional relationships in major depressive disorder: crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. J Affect Disord. 2019;250:114\u201322.","journal-title":"J Affect Disord"},{"key":"2636_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, \u00c5sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"2636_CR17","first-page":"217","volume-title":"ECDEU assessment manual for psychopharmacology revised","author":"W Guy","year":"1976","unstructured":"Guy W. Clinical Global Impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology revised. Rockville: National Institute of Mental Health; 1976. p. 217\u201322."},{"key":"2636_CR18","first-page":"242","volume-title":"Cognitive impairment in major depressive disorder: clinical relevance, biological substrates, and treatment opportunities","author":"D Cha","year":"2016","unstructured":"Cha D. Perceived deficits questionnaire \u2013 depression, 5-item (PDQ-D-5). In: McIntyre R, editor. Cognitive impairment in major depressive disorder: clinical relevance, biological substrates, and treatment opportunities. Cambridge: Cambridge University Press; 2016. p. 242\u201356."},{"key":"2636_CR19","volume-title":"A compendium of neuropsychological tests: administration, norms, and commentary","author":"E Strauss","year":"2006","unstructured":"Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological tests: administration, norms, and commentary. Oxford, England: Oxford University Press; 2006."},{"issue":"1","key":"2636_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/EDE.0b013e31827825f2","volume":"24","author":"F Habibzadeh","year":"2013","unstructured":"Habibzadeh F, Yadollahie M. Number needed to misdiagnose: a measure of diagnostic test effectiveness. Epidemiology. 2013;24(1):170.","journal-title":"Epidemiology."},{"key":"2636_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0306-4530(97)00046-2","volume":"22","author":"M Deuschle","year":"1997","unstructured":"Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, K\u00f6rner A, et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology. 1997;22:493\u2013503.","journal-title":"Psychoneuroendocrinology."},{"key":"2636_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1600-0447.1988.tb06404.x","volume":"78","author":"KP Lesch","year":"1988","unstructured":"Lesch KP, Rupprecht R, M\u00fcller U, Pf\u00fcller H, Beckmann H. Insulin-like growth factor I in depressed patients and controls. Acta Psychiatr Scand. 1988;78:684\u20138.","journal-title":"Acta Psychiatr Scand"},{"key":"2636_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0022-3956(98)00066-1","volume":"33","author":"B Franz","year":"1999","unstructured":"Franz B, Buysse DJ, Cherry CR, Gray NS, Grochocinski VJ, Frank E, et al. Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J Psychiatr Res. 1999;33:121\u20137.","journal-title":"J Psychiatr Res"},{"key":"2636_CR24","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.euroneuro.2014.12.013","volume":"25","author":"A Kopczak","year":"2015","unstructured":"Kopczak A, Stalla GK, Uhr M, Lucae S, Hennings J, Ising M, et al. IGF-I in major depression and antidepressant treatment response. Eur Neuropsychopharmacol. 2015;25:864\u201372.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2636_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.psyneuen.2016.02.028","volume":"68","author":"M Bot","year":"2016","unstructured":"Bot M, Milaneschi Y, Penninx BW, Drent ML. Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users. Psychoneuroendocrinology. 2016;68:148\u201355.","journal-title":"Psychoneuroendocrinology."},{"key":"2636_CR26","doi-asserted-by":"publisher","first-page":"e2411","DOI":"10.1097\/MD.0000000000002411","volume":"95","author":"KY Tu","year":"2016","unstructured":"Tu KY, Wu MK, Chen YW, Lin PY, Wang HY, Wu CK, et al. Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA. Medicine (Baltimore). 2016;95:e2411.","journal-title":"Medicine (Baltimore)"},{"key":"2636_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1575-0922(08)75076-9","volume":"55","author":"S Rueda Alfaro","year":"2008","unstructured":"Rueda Alfaro S, Serra-Prat M, Palomera E, Falcon I, Cadenas I, Boquet X, et al. Hormonal determinants of depression and cognitive function in independently-living elders. Endocrinol Nutr. 2008;55:396\u2013401.","journal-title":"Endocrinol Nutr"},{"key":"2636_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1210\/jcem.84.2.5455","volume":"84","author":"A Aleman","year":"1999","unstructured":"Aleman A, Verhaar HJ, De Haan EH, De Vries WR, Samson MM, Drent ML, et al. Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab. 1999;84:471\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"2636_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.psyneuen.2014.01.006","volume":"42","author":"F Lin","year":"2014","unstructured":"Lin F, Suhr J, Diebold S, Heffner KL. Associations between depressive symptoms and memory deficits vary as a function of insulin-like growth factor (IGF-1) levels in healthy older adults. Psychoneuroendocrinology. 2014;42:118\u201323.","journal-title":"Psychoneuroendocrinology."},{"key":"2636_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pnpbp.2013.01.008","volume":"44","author":"A Palomino","year":"2013","unstructured":"Palomino A, Gonzalez-Pinto A, Martinez-Cengotitabengoa M. Ruiz de Azua S, Alberich S, Mosquera F, et al. relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;44:29\u201333.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2636_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1210\/edrv-14-1-20","volume":"14","author":"E Corpas","year":"1993","unstructured":"Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14:20\u201339.","journal-title":"Endocr Rev"},{"key":"2636_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2147\/CIA.S3697","volume":"3","author":"A Bartke","year":"2008","unstructured":"Bartke A. Growth hormone and aging: a challenging controversy. Clin Interv Aging. 2008;3:659\u201365.","journal-title":"Clin Interv Aging"},{"key":"2636_CR33","doi-asserted-by":"publisher","first-page":"109610","DOI":"10.1016\/j.mehy.2020.109610","volume":"138","author":"OA Levada","year":"2020","unstructured":"Levada OA, Troyan AS. Major depressive disorder and accelerated aging from a peripheral IGF-1 overexpression perspective. Med Hypotheses. 2020;138:109610.","journal-title":"Med Hypotheses"},{"issue":"3","key":"2636_CR34","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/JCP.0b013e3182189d86","volume":"31","author":"C Schilling","year":"2011","unstructured":"Schilling C, Blum WF, Heuser I, Paslakis G, Wudy SA, Deuschle M. Treatment with antidepressants increases insulin-like growth factor-I in cerebrospinal fluid. J Clin Psychopharmacol. 2011;31(3):390\u20132.","journal-title":"J Clin Psychopharmacol"},{"key":"2636_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/s-0028-1085442","volume":"42","author":"B Weber-Hamann","year":"2009","unstructured":"Weber-Hamann B, Blum WF, Kratzsch J, Gilles M, Heuser I, Deuschle M. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry. 2009;42:23\u20138.","journal-title":"Pharmacopsychiatry."},{"key":"2636_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jad.2016.02.067","volume":"197","author":"AN Sharma","year":"2016","unstructured":"Sharma AN. da Costa e Silva BF, Soares JC, Carvalho AF, Quevedo J. role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: a comprehensive review of human studies. J Affect Disord. 2016;197:9\u201320.","journal-title":"J Affect Disord"},{"issue":"5","key":"2636_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1083\/jcb.200106139","volume":"155","author":"S Taya","year":"2001","unstructured":"Taya S, Inagaki N, Sengiku H, Makino H, Iwamatsu A, Urakawa I, et al. Direct interaction of insulin-like growth factor-1 receptor with leukemia-associated RhoGEF. J Cell Biol. 2001;155(5):809\u201320.","journal-title":"J Cell Biol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02636-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02636-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T19:11:18Z","timestamp":1620414678000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02636-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2636"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02636-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"2 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the Zaporizhzhia Medical Academy of Postgraduate Education Ethics Committee - Zaporizhzhia, Ukraine, on 15th September 2016. All participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"O.A. Levada is a member of advisory and\/or speaker boards of the following companies: Lundbeck, Pfizer, Acino. A.S. Troyan gave presentations for Lundbeck and Acino.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}